Used in peptide synthesis as a chiral building block for constructing structurally modified peptides with enhanced stability and biological activity. The Fmoc group enables solid-phase synthesis by allowing stepwise addition of amino acids under mild conditions. The (R)-3-amino-4-(4-methylphenyl)butyric acid moiety introduces a sterically hindered, hydrophobic side chain that can influence peptide conformation, receptor selectivity, and metabolic resistance. Commonly applied in the development of peptidomimetic drugs, especially in oncology and CNS-targeted therapeutics where aromatic and chiral elements improve target binding. Its structure supports beta-turn formation in peptides, making it valuable in designing foldamers and constrained peptides.